Sheet <u>1</u> of <u>1</u>

Substitute Form PTO-1449 FM & TRAS Application No. Department of Commerce Attorney's Docket No. (Modified) Patent and Trademark Office 17111-007US1/2307US 09/601,997 **Applicant** List of Patents and Publications for Applicant's James Keck et al. **Information Disclosure Statement** Filing Date **Group Art Unit** December 15, 2000 1635 (37 CFR §1.98(b)) **U.S. Patent Documents** Examiner Desig. **Document Publication** Filing Date If Appropriate Initial ID Number Date Patentee Class Subclass Keck et al. A. 2003/0087288 05/08/03 435 09/16/02 6 5,593,884 01/14/97 В. Karin et al. 435 252.3 07/18/94 C. 6,448,009 09/10/02 Thompson 435 6 09/29/00 D. 6,803,194 6 10/12/04 Keck et al. 435 08/09/00

Foreign Patent Documents or Published Foreign Patent Applications									
Exáminer	Desig.	Document	Publication	Country or			Trans	slation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
(B)	E.	99/32618	07/01/99	PCT					
1/1	F.	99/41371	08/19/99	PCT					

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner	Desig.						
Initial	ID	Document					
B	G.	James, H.A. and I. Gibson, "The Therapeutic Potential of Ribozymes," Blood 91(2): 371-382 (1998)					
	Н.	Lieber et al., "Elimination of Hepatitis C Virus RNA in Infected Human Hepatocytes by Adenovirus-Mediated Expression of Ribozymes," Journal of Virology 70(12): 8782-8791 (1996)					

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.